About Ambrx
Ambrx (Nasdaq: AMAM) is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications. Specifically, ARX517, its proprietary antibody-drug conjugates (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx’s protein engineering technology.
|
|
|
51-200 employees
View all Ambrx employees
|
|
Biotechnology
|
|
10975 N Torrey Pines Rd, San Diego, CA 92037, US
|
|
2003
|
Ambrx Alternatives
Frequently Asked Questions about Ambrx
Lawson Macartney is the CEO of Ambrx. To contact Lawson Macartney email at [email protected].
The decision makers in Ambrx are Colin Hessel, Douglas Pierce, Johanna Acosta, etc. Click to Find Ambrx decision makers emails.
Ambrx Staff Directory
Search Ambrx Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.
